A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
Chronic kidney disease (CKD) is a commonly diagnosed condition, affecting approximately 30 million adults in the United States.1 CKD refers to a diverse group of pathologies that result in kidney function decline for at least 3 months.2,3 Kidney disease etiologies are generally classified into 3 categories: prerenal, intrinsic renal, and postrenal. Prerenal disease is marked…
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
A study of patients with chronic kidney disease found that regular and occasional binge drinkers had double the risk of disease progression compared with non-drinkers.
Mortality rates significantly higher for territory-dwelling Hispanic and Asian dialysis patients
Safety net-reliant patients more likely to initiate dialysis at nonprofit/independently owned facilities.
Increasing levels of fibroblast growth factor 23 in patients with chronic kidney disease are independently associated with an increased risk of requiring maintenance dialysis or a kidney transplant, a study found.
Compared with never-drinkers, individuals who consumed 2 to 7, 8 to 14, and 15 or more drinks per week had significant 12%, 20%, 29%, and 23% decreased risks of incident chronic kidney disease, respectively, in adjusted analyses, according to a new report.
Full study results will be presented at an oral plenary session at the OxalEurope International Congress on Tuesday, March 31, 2020.
The FDA has accepted for review the New Drug Application (NDA) for veverimer (TRC101; Tricida) for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).